Cytoplasm

Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th

Retrieved on: 
Tuesday, January 10, 2023
Altamira, Tissue, RNA transfection, Semaphore, LNP, Conference, Protein, Therapy, RNA, Research, Medicine, Liver, Cytoplasm, Medical device, Vaccine

Altamira is developing the use of mRNA to therapeutically increase the local production of specific proteins outside the liver to treat a variety of diseases.

Key Points: 
  • Altamira is developing the use of mRNA to therapeutically increase the local production of specific proteins outside the liver to treat a variety of diseases.
  • For this purpose, the Company is using its SemaPhore platform to efficiently transport those mRNA payloads into extrahepatic target cells.
  • Even the most powerful mRNA molecule is useless, however, if it cannot be delivered safely and effectively to the target tissue.
  • With our SemaPhore platform, we have the right technology to take mRNA where it is needed and release it efficiently inside target cells.”

EQS-News: Defence Therapeutics Inc.: mRNA WITH DEFENCE’S ACCUMTM PROGRAM HAS BEEN INITIATED

Retrieved on: 
Sunday, January 22, 2023
Quality control, Protein, RNA transfection, Therapy, Quality control in tissue engineering, Cytoplasm, USD, Animal, Infection, Egg cell, Defense, Vaccine, Neoplasm

Vancouver, BC, Canada, January 10th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement in the development of its AccumTM -mRNA vaccine program.

Key Points: 
  • Vancouver, BC, Canada, January 10th, 2023 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement in the development of its AccumTM -mRNA vaccine program.
  • The mRNA vaccination approach offers tremendous advantages over the use of peptide- or protein-based vaccines.
  • Defence is working with a private European company to synthesize mRNA vaccine coupled with its AccumTM.
  • Defence is advancing on the second step, which consists of coupling AccumTM variants to amino-modified mRNA as well as testing and analyzing: i) the effect of AccumTM and linkers on mRNA stability, ii) the linker coupling onto amino-modified mRNA, iii) the AccumTM coupling onto linker-amino modified mRNA, and finally iv) the purification and analysis of the AccumTM-linker-amino-modified mRNA.

ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Pancreatic Cancer

Retrieved on: 
Tuesday, December 27, 2022
Patient, Plectin, Cancer, Food, CSP, Cytoplasm, FDA, Metastasis, Safety, Pancreatic cancer, China Biologic Products, Multimedia, Cholangiocarcinoma, Pancreas, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Orphan, Woman, Pharmaceutical industry

CHARLOTTESVILLE, Va., Dec. 27, 2022 /PRNewswire/ -- ZielBio, Inc., a clinical-stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative drug discovery platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead program, ZB131, for the treatment of treatment of pancreatic cancer, a rare solid-tumor cancer originating from the pancreas. ZB131 is a proprietary monoclonal antibody with a high affinity and specificity for cancer-specific plectin (CSP), a cell surface protein identified in a wide range of cancers that correlates with poor prognosis and aggressive tumors, including pancreatic cancer. ZielBio previously received Orphan Drug Designation for ZB131 for the treatment of cholangiocarcinoma (bile duct cancer).

Key Points: 
  • CHARLOTTESVILLE, Va., Dec. 27, 2022 /PRNewswire/ -- ZielBio, Inc., a clinical-stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative drug discovery platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead program, ZB131, for the treatment of treatment of pancreatic cancer, a rare solid-tumor cancer originating from the pancreas.
  • ZielBio previously received Orphan Drug Designation for ZB131 for the treatment of cholangiocarcinoma (bile duct cancer).
  • "We appreciate the special status that the FDA has granted ZB131 with this Orphan Drug Designation for pancreatic cancer, which is typically diagnosed at an advanced stage with few effective treatment options."
  • Certain benefits associated with Orphan Drug Designation encourage the continued development of medicines that bring novel solutions to underserved patients.

EQS-News: Defence Therapeutics Inc.: DEFENCE'S mRNA WITH ACCUMTM FOR CANCER VACCINES UPDATE

Retrieved on: 
Sunday, December 18, 2022
Cell, Protein, Neoplasm, Vaccination, Animal, Catastrophic illness, Engineering, Cancer, ADC, Control, News, Vaccine, Cytoplasm, CSE, RNA transfection, USD, Infection, Therapy, Security (finance), Pharma, Defense

The Defence team is therefore working with a private European company to synthesize mRNA vaccines coupled with AccumTM.

Key Points: 
  • The Defence team is therefore working with a private European company to synthesize mRNA vaccines coupled with AccumTM.
  • The objective of this study is to demonstrate that AccumTM can significantly enhance the therapeutic potency of a given mRNA vaccine”, says Mr. Plouffe, CEO of Defence Therapeutics.
  • “Once completed, Defence will have in its possession its own 100% owned mRNA with AccumTM vaccine for cancer.
  • Defence will also be in a position to license its personalized AccumTM technology to any Pharma company with mRNA vaccines”, he adds.

Sapience Therapeutics Announces Appointment of Abi Vainstein-Haras, M.D. as Chief Medical Officer

Retrieved on: 
Thursday, December 1, 2022
Innovation, BioLineRx, Permeability, Drug, Peptide, Hematologic disease, MS, Teva, Glioblastoma, University, Cancer, IND, University of Buenos Aires, Therapy, Factor X, Patient, Running, Drug development, NDA, C/EBP, Multiple sclerosis, Phase II, CMO, Publication, Cytoplasm, Traffic barrier, PPI, Pharmaceutical industry, Vaccine, Wisdom, Spear

HARRISON, N.Y., Dec. 1, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, announced today the appointment of Dr. Abi Vainstein-Haras as Chief Medical Officer, effective December 1, 2022. Dr. Alice S. Bexon, who has served as a clinical advisor since 2017 and as Sapience's consulting Chief Medical Officer since 2019, will continue in an advisory role to support the transition to Dr. Vainstein-Haras and beyond. In addition, Dr. Bexon's clinical consulting group, Bexon Clinical, will continue to support the development of Sapience's clinical-stage pipeline and strategy. 

Key Points: 
  • HARRISON, N.Y., Dec. 1, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, announced today the appointment of Dr. Abi Vainstein-Haras as Chief Medical Officer, effective December 1, 2022.
  • "We are thrilled to welcome Abi to Sapience as Chief Medical Officer," commented Dr. Barry Kappel, CEO and President of Sapience.
  • She joins Sapience from BioLineRx, where she spent the last eight years serving in multiple roles of increasing responsibility, most recently serving as Chief Medical Officer sinceJanuary 2021.
  • "It has been my honor to serve as Chief Medical Officer of Sapience for the past three years," said Dr. Bexon.

$5.1 Billion Histology and Cytology In Vitro Diagnostics (IVD) Market, reports Kalorama Information

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Growth, IVD, Diagnosis, Cell nucleus, Elastin, Paraffin, Kidney, Cell, DNA, Histology, Tissue, Congo red, Fluid mechanics, Hybridization probe, Enzyme, H&E, Virulence, PAS, Physician, Organic acid, Protein, In situ hybridization, Fiber, FISH, COVID, Cancer, HPV, ISH, Sputum, Therapy, Cytoplasm, Immunohistochemistry, Marie Cassidy, Iron, IHC, Liver, HIV disease progression rates, Medical imaging, Microscope, Ralph E. Gomory

ARLINGTON, Va., Nov. 30, 2022 /PRNewswire-PRWeb/ -- 

Key Points: 
  • The market for the testing of tissues and cells, histology and cytology in vitro diagnostics reached $4.9 billion in 2021 per market research firm Kalorama Information and is expected to grow to $5.1 billion in 2022.
  • The global histology IVD market grew 23.5% from 2020 to 2021 reflecting strong rebounding after the market experienced negative effects from the COVID-19 pandemic during 2020.
  • The market stabilized from COVID and now Kalorama Information analysts expect a 4.2% CAGR.
  • All of these techniques involve analyzing cells either in surgical and biopsied tissue (histology) or body fluids (cytology).

Global Protein Expression Market Size, Share & Industry Trends Analysis Report by System, Product, Application, End-user, Regional Outlook and Forecast, 2022-2028

Retrieved on: 
Thursday, November 24, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Infection, Rheumatoid arthritis, RNA, Protein, Biotechnology, Probability, Organic acid, Drug development, Diagnosis, Genetic engineering, CFPS, RNA transfection, Water, Cytoplasm, PCR, DNA, Medicine, Fine chemical, Vaccine, Adalimumab

The "Global Protein Expression Market Size, Share & Industry Trends Analysis Report by System, Product, Application, End-user, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Protein Expression Market Size, Share & Industry Trends Analysis Report by System, Product, Application, End-user, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Protein Expression Market size is expected to reach $4.9 billion by 2028, rising at a market growth of 10.1% CAGR during the forecast period.
  • Therefore, the novel technique can accelerate the development of the cell-free expression industry, which is expected to expand the protein expression market.
  • As a result, the cost of producing CFPE on a big scale makes it risky for the expansion of the protein expression market.

ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Cholangiocarcinoma

Retrieved on: 
Tuesday, November 15, 2022
Cholangiocarcinoma, Cancer, Orphan, Metastasis, Patient, Liver, Safety, CSP, FDA, View, China Biologic Products, Cytoplasm, CEO, Plectin, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

CHARLOTTESVILLE, Va., Nov. 15, 2022 /PRNewswire/ -- ZielBio, Inc., a clinical-stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative drug discovery platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead program, ZB131, for the treatment of cholangiocarcinoma, a rare solid-tumor cancer originating from the bile duct system. ZB131 is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin (CSP), a cell surface protein identified in a wide range of cancers that correlates with poor prognosis and aggressive tumors. 

Key Points: 
  • "Patients suffering from cholangiocarcinoma have few promising therapeutic options," said Kimberly Kelly, Ph.D., founder and CEO of ZielBio.
  • "Receiving this Orphan Drug Designation is a regulatory milestone for ZielBio that validates our sustained efforts to bring new treatments to underserved patients."
  • A Phase 1/2 trial is underway to study the safety, tolerability, and efficacy of ZB131 in patients with solid tumors, including cholangiocarcinoma, pancreatic, and ovarian cancers.
  • ZielBio has a promising pipeline of therapies and targets, including lead asset ZB131, a proprietary humanized monoclonal antibody against cancer-specific plectin.

5th World Laureates Forum opens with the inaugural WLA Prize award ceremony

Retrieved on: 
Wednesday, November 9, 2022
Zero, Max Planck Society, Computer Sciences, Department, Nobel Prize, Machine learning, UC, University of California, Berkeley, WLA, Science, Computer science, Cytoplasm, Conference, Department of Statistics, Mathematics, Electrical engineering, Medicine, Pharmaceutical industry, Chemistry

SHANGHAI, Nov. 9, 2022 /PRNewswire/ --The fifth World Laureates Forum, or WLA Forum, successfully held in Shanghai,featuring 60 top scientists worldwide, including 27 Nobel Prize laureates.

Key Points: 
  • SHANGHAI, Nov. 9, 2022 /PRNewswire/ --The fifth World Laureates Forum, or WLA Forum, successfully held in Shanghai,featuring 60 top scientists worldwide, including 27 Nobel Prize laureates.
  • Beforeits official opening, various meetings and events, including WLA Zero CarbonForum, WLA SHE Forum, the WLA Sci-T Conference, and the newly-launched WLALaboratories Forum, have been held since 29 October.
  • (Follow WLA Forum atTwitter & Facebook @wlaforum)
    Notably, the inaugural World Laureates Association Prize (WLA Prize) wasawarded to two scientists at the opening ceremony on 6 November.
  • Dirk Gorlich, 2022 WLA Prize Laureate in Life Science or Medicine - "I feltsurprised and very happy.

5th World Laureates Forum opens with the inaugural WLA Prize award ceremony

Retrieved on: 
Tuesday, November 8, 2022
Zero, Carbon, Computer Sciences, Department, Nobel Prize, Machine learning, UC, University of California, Berkeley, WLA, Science, Computer science, Cytoplasm, Protein, Conference, Department of Statistics, Mannheim School of Computer Science and Mathematics, Mathematics, Electrical engineering, Foundation, Medicine, Pharmaceutical industry, Chemistry

SHANGHAI, Nov. 8, 2022 /PRNewswire/ -- The fifth World Laureates Forum, or WLA Forum, successfully held in Shanghai, featuring 60 top scientists worldwide, including 27 Nobel Prize laureates.

Key Points: 
  • SHANGHAI, Nov. 8, 2022 /PRNewswire/ -- The fifth World Laureates Forum, or WLA Forum, successfully held in Shanghai, featuring 60 top scientists worldwide, including 27 Nobel Prize laureates.
  • Before its official opening, various meetings and events, including WLA Zero Carbon Forum, WLA SHE Forum, the WLA Sci-T Conference, and the newly-launched WLA Laboratories Forum, have been held since 29 October.
  • (Follow us at Twitter&Facebook @wlaforum)
    Notably, the inaugural World Laureates Association Prize (WLA Prize) was awarded to two scientists at the opening ceremony on 6 November.
  • Dirk Gorlich, 2022 WLA Prize Laureate in Life Science or Medicine-"I felt surprised and very happy.